力恩普制药Lean&Leap

NEWS

CDE accepts two supplementary applications for Amoxicillin and Clavulanate Potassium for Suspension

2025-06-27 · Company News

← Back to news

In June 2025, the Center for Drug Evaluation (CDE) of NMPA accepted two supplementary applications (CYHB2550240, CYHB2550241) for our Amoxicillin and Clavulanate Potassium for Suspension, further advancing the oral portfolio.